title: Bladder preservation protocols in the treatment of muscle-invasive bladder cancer.
abstract: BACKGROUND
  Over the last 3 decades, we have seen a paradigm shift in our approach to the treatment of malignancy. During that time, organ conservation protocols have become standard in the treatment of breast cancer, laryngeal cancer, esophageal cancer, anal cancer and soft tissue sarcomas.
  
  
  METHODS
  Data from reports of bladder preservation protocols were reviewed to evaluate organ preservation approaches in muscle-invasive bladder cancer.
  
  
  RESULTS
  These trials have shown equivalent disease control rates when compared to radical surgery, with the advantage of organ function preservation. In spite of this, organ preservation efforts in muscle-invasive bladder cancer have lagged behind this overall trend in clinical oncology. However, efforts by several investigators over the last 2 decades have shown that for a number of selected patients with muscle-invasive bladder cancer, bladder preservation is feasible without an apparent compromise of overall survival.
  
  
  CONCLUSIONS
  Bladder preservation therapy with a trimodality approach for a carefully selected patient population is safe and effective. Formal randomized trials comparing radical cystectomy and trimodality bladder-sparing therapy are justified.
authors.affiliation: Department of Interdisciplinary Oncology and the Radiation Oncology Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA. torresjf@moffitt.usf.edu
authors.forename: Javier F
authors.initials: JF
authors.lastname: Torres-Roca
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D015653:Cystectomy; D005069:Evaluation Studies as Topic; D006801:Humans; D018787:Radiation Oncology / Q000458:organization & administration; D011878:Radiotherapy / Q000379:methods; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents